These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36495880)

  • 61. Association between skin and joint involvement in patients with psoriatic arthritis treated with adalimumab: analysis of data from a German non-interventional study.
    Thaçi D; Behrens F; Greger G; Burkhardt H; Gnann H; Schopf R; Wittig BM
    Dermatology; 2015; 230(3):213-21. PubMed ID: 25632852
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?
    Rallis E; Korfitis C; Stavropoulou E; Papaconstantis M
    J Dermatolog Treat; 2010 Jan; 21(1):3-5. PubMed ID: 19701844
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical improvement in psoriatic nail disease and psoriatic arthritis with tildrakizumab treatment.
    Ismail FF; May J; Moi J; Sinclair R
    Dermatol Ther; 2020 Mar; 33(2):e13216. PubMed ID: 31899569
    [No Abstract]   [Full Text] [Related]  

  • 64. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
    Kiltz U; Sfikakis PP; Gaffney K; Sator PG; von Kiedrowski R; Bounas A; Gullick N; Conrad C; Rigopoulos D; Lespessailles E; Romanelli M; Ghislain PD; Brandt-Jürgens J; Rashkov R; Aassi M; Orsenigo R; Perella C; Pournara E; Gathmann S; Jagiello P; Veit J; Augustin M
    Adv Ther; 2020 Jun; 37(6):2865-2883. PubMed ID: 32378070
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comment on: 'Paradoxical psoriatic arthritis in a patient with psoriasis treated with guselkumab'.
    Akturk S; Altunisik N; Buyukavci R; Turkmen D
    Clin Exp Dermatol; 2022 Jul; 47(7):1363-1364. PubMed ID: 35266569
    [No Abstract]   [Full Text] [Related]  

  • 66. Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis.
    Cai L; Zhang JZ; Zheng M; Zhang SF; Patekar M
    Chin Med J (Engl); 2021 Sep; 134(21):2629-2631. PubMed ID: 34748527
    [No Abstract]   [Full Text] [Related]  

  • 67. A case of twins affected by psoriasis, psoriatic arthritis and autism: Five years of efficacious and safe treatment with Secukinumab.
    Bernardini N; Skroza N; Marraffa F; Prevete E; Mambrin A; Proietti I; Tolino E; Caviglia M; Di Guardo A; Rossi G; Volpe S; Bersani G; Potenza C
    Dermatol Ther; 2022 Jul; 35(7):e15533. PubMed ID: 35460156
    [No Abstract]   [Full Text] [Related]  

  • 68. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
    Gottlieb A; Korman NJ; Gordon KB; Feldman SR; Lebwohl M; Koo JY; Van Voorhees AS; Elmets CA; Leonardi CL; Beutner KR; Bhushan R; Menter A
    J Am Acad Dermatol; 2008 May; 58(5):851-64. PubMed ID: 18423261
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
    JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Is there a need for new agents with novel mechanisms of action in psoriatic arthritis?
    Orr C; Veale DJ
    Ann Rheum Dis; 2014 Jun; 73(6):951-3. PubMed ID: 24790066
    [No Abstract]   [Full Text] [Related]  

  • 71. Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report.
    Lu J; Tang S; Yu N; Yi X; Li Y
    J Int Med Res; 2020 Nov; 48(11):300060520969494. PubMed ID: 33161790
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
    Blegvad C; Skov L; Zachariae C
    Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
    [No Abstract]   [Full Text] [Related]  

  • 73. Efficacy and safety of ixekizumab in psoriatic arthritis: a retrospective, single-centre, observational study in a real-life clinical setting.
    Manfreda V; Chimenti MS; Canofari C; Esposito M; Perricone R; Bianchi L; Giunta A
    Clin Exp Rheumatol; 2020; 38(3):581-582. PubMed ID: 32105590
    [No Abstract]   [Full Text] [Related]  

  • 74. Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight.
    Nguyen CT; Bloch Y; Składanowska K; Savvides SN; Adamopoulos IE
    Clin Immunol; 2019 Sep; 206():15-22. PubMed ID: 30196070
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab.
    Chew AL; Bennett A; Smith CH; Barker J; Kirkham B
    Br J Dermatol; 2004 Aug; 151(2):492-6. PubMed ID: 15327561
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Biological treatment of psoriasis and psoriatic arthritis].
    Kragballe K; Deleuran B
    Ugeskr Laeger; 2008 Jun; 170(24):2148-50. PubMed ID: 18565300
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Cutaneous pseudolymphoma with two types of anti-TNFα: a class effect?].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2012 Oct; 139(10):695-6. PubMed ID: 23122389
    [No Abstract]   [Full Text] [Related]  

  • 80. Long-term tocilizumab efficacy in a patient with psoriatic arthritis and AA amyloidosis.
    Dinoia L; Lopalco G; Cantarini L; Gesualdo L; Rossini M; Iannone F
    Clin Exp Rheumatol; 2017; 35(1):170-171. PubMed ID: 27908297
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.